Stock Screener App

Frei -

Installieren

213.02

0.24% 0.5235

Biogen Inc (BIIB)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BIIB? Forum Prognose Aktiensplit

Biogen Inc Aktie (BIIB) Neueste Nachrichten

Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com Canada

Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing - simplywall.st

Biogen Inc (BIIB) Shares Fall 3.8% -- What GF Score of 73 Tells Investors - GuruFocus

Biogen Must Face Pharmacies' MS Drug Monopoly Suit - Law360

(BIIB) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Lilly Builds Neuroscience into a New Long-Term Growth Driver - Zacks Investment Research

Biogen stock heads into the open without fresh price data - AD HOC NEWS

Biogen Inc. (BIIB) Investor Outlook: Navigating Growth in the Healthcare Sector with a Potential 7.26% Upside - DirectorsTalk Interviews

Biogen Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus

Biogen Inc. stock holds near 12 month high on steady Q1 2026 growth - AD HOC NEWS

BIIB Stock Price Prediction 2026-2027 | Biogen Forecast - 24/7 Wall St.

Biogen Inc. (BIIB) Peer Comparison – Compare with Others - Value Research

Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi - marketscreener.com

Biogen (BIIB), Why Is Its Latest Update Drawing Fresh Attention? - simplywall.st

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Biogen

Stoke Therapeutics and Biogen Present Long-Term Clinical - GlobeNewswire

Biogen (BIIB) awards 7,405 stock units to its top lawyer - Stock Titan

Biogen Is Repositioning Its Portfolio To Partly Offset Ongoing Revenue Declines - Morningstar

Piper Sandler raises Biogen stock price target on pipeline outlook - Investing.com

Eisai, Biogen Win China Approval for Leqembi Self-Injection - International Business Times

Price cut becomes the price of coverage for Alzheimer's drug lecanemab - Benefits and Pensions Monitor

Biogen Inc. (BIIB) Key Financial Ratios – Valuation, Profitability & More - Value Research

Eisai and Biogen Announce China Approval of LEQEMBI SC-AI for Initiation Treatment of Early Alzheimer’s Disease - Quiver Quantitative

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China - Biogen

Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data - Yahoo Finance

How Biogen’s (BIIB) At-Home LEQEMBI Injections Could Reframe the Alzheimer’s Treatment Investment Story - simplywall.st

Biogen Inc (BIIB) Shares Surge 3.1% -- What GF Score of 73 Tells Investors - GuruFocus

Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch

Biogen gains as pipeline updates and fresh Street target hikes buoy sentiment - Quiver Quantitative

Biogen stock hits 52-week high at 222.86 USD By Investing.com - Investing.com Canada

Biogen stock hits 52-week high at 222.86 USD - Investing.com

A potential seizure treatment will be presented Sept. 9 by Stoke Therapeutics - Stock Titan

Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet - Yahoo Finance

Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome - Investing.com

Stoke, Biogen Present 4-Year Dravet Syndrome Data at EEC | BIIB Stock News - Stock Titan

Eisai and Biogen Announce Canada’s Drug Agency Final Recommendation Supporting Public Reimbursement of LEQEMBI for Eligible Early Alzheimer’s Disease Patients - Quiver Quantitative

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease - Biogen

Final CDA-AMC Recommendation Brings Canadians with Early-Stage Alzheimer's Disease One Step Closer to Accessing LEQEMBI® (lecanemab) - PR Newswire Canada

Price to book forward of Biogen Inc. – NASDAQ:BIIB - TradingView

Biogen Inc. (BIIB) Stock Report: Analyst Ratings Signal Potential Upside Of Over 8% - DirectorsTalk Interviews

Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch

Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report? - Yahoo Finance

Will Biogen (BIIB) Make Early Alzheimer’s Treatment Easier At Home? - simplywall.st

RBC Capital raises Biogen stock price target on lupus drug potential - Investing.com

Eisai and Biogen Launch LEQEMBI IQLIK Subcutaneous Injection for Early Alzheimer’s Disease in the U.S. - Quiver Quantitative

Biogen Inc. (BIIB) Stock Analysis: Evaluating a Potential 8.67% Upside in the Healthcare Sector - DirectorsTalk Interviews

How Investors Are Reacting To Biogen (BIIB) Raising EPS Guidance On Late-Stage Drug Trial Milestones - simplywall.st

Biogen Expands Autoimmune Pipeline With New Graves’ Disease Trial - TipRanks

Biogen Inc. (NASDAQ:BIIB) Healthcare Momentum Draws Fresh Market Attention - Kalkine Media

What Biogen (BIIB)'s Higher Earnings Guidance and Late-Stage Pipeline Progress Means For Shareholders - Yahoo Finance

OVERSEA CHINESE BANKING Corp Ltd Purchases Shares of 18,867 Biogen Inc. $BIIB - MarketBeat

Wealthfront Advisers LLC Acquires Shares of 16,529 Biogen Inc. $BIIB - MarketBeat

OVERSEA CHINESE BANKING Corp Ltd Acquires Shares of 13,000 Biogen Inc. $BIIB - MarketBeat

66,365 Shares in Biogen Inc. $BIIB Bought by Danske Bank A S - MarketBeat

Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Biogen (BIIB) And The Alzheimer’s Narrative As Valuation Stays In Focus - simplywall.st

Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month? - TradingView

Impax Global Women's Leadership Fund's Biogen Inc(BIIB) Holding History - GuruFocus

Is Wall Street Bullish or Bearish on Biogen Stock? - Barchart.com

Meeder Advisory Services Inc. Acquires Shares of 4,608 Biogen Inc. $BIIB - MarketBeat

Edmond DE Rothschild Holding S.A. Makes New Investment in Biogen Inc. $BIIB - MarketBeat

BIIB Stock Price Prediction 2025-2026 | Biogen Inc Forecast - 24/7 Wall St.

Biogen Inc (BIIB) Stock Up 4.2% but GF Value Says Overvalued -- GF Score: 73/100 - GuruFocus

Biogen (NASDAQ:BIIB) Sets New 1-Year HighTime to Buy? - MarketBeat

Biogen (BIIB) Stock Surges to 52-Week Peak After BlackRock’s $3.4B Investment - Blockonomi

Biogen stock hits 52-week high at 219.94 USD - Investing.com

PFE

$27.89

0.25%

GILD

$146.34

0.54%

NVO

$44.94

0.59%

AMGN

$392.92

0.02%

AZN

$157.92

1.30%

NVS

$137.92

0.41%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters